Q1 2027 Elite Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Elite Pharmaceuticals Inc (ELTP) reported steady revenues of $32.4 million and operating profits of $7.5 million for Q1 FY2027, in line with the previous three quarters.
- The company's market share increased across all major products, including Lisdex, Amphetamine IR, Amphetamine ER, and Naltrexone, with overall volumes up 14.75% year-over-year.
- Elite Pharmaceuticals Inc (ELTP) has a robust pipeline, including a successful BE study for an undisclosed anticonvulsant product with $840 million in annual brand sales, and an undisclosed anticoagulant product with $26 billion in sales.
- The company's cash position strengthened to $38.9 million, up from $29.8 million at the beginning of the year, with strong operating cash flow of $10.1 million.
- Elite Pharmaceuticals Inc (ELTP) is well-positioned to benefit from potential US tariffs on generic finished products, which would give it a competitive advantage over foreign manufacturers and make it an attractive acquisition target.
- The company is actively pursuing a Nasdaq uplisting, with a target to finalize by February 2027, which could enhance shareholder value.
- Elite Pharmaceuticals Inc (ELTP) experienced a year-over-year revenue decline compared to the extraordinary June 2025 quarter, which was boosted by the initial launch of generic Vyvanse at higher prices.
- The company faces pricing pressure in the generic market, particularly for Lisdex, as competition increased and prices corrected to a lower steady state.
- Elite Pharmaceuticals Inc (ELTP) has a high customer concentration, with its largest customer accounting for 60% of revenues, though management attributes price changes to market dynamics rather than customer power.
- The Oxy ER product launch is delayed due to an unresolved FDA issue regarding in-vitro anti-abuse smokability, which could impact the August 2027 launch timeline.
- Working capital decreased to $84.1 million from $94.7 million, primarily due to a $17 million noncash warrant derivative liability reclassified as current, though this is a noncash accounting change.
- The company's M&A and uplisting plans remain uncertain, with no definitive timeline for a transaction, and the warrant resolution is pending until April 2027.
Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals first quarter of fiscal year 2027 conference call. (Operator Instructions)
Before management begins speaking, the conference has the following statement. Elite would like to remind listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties that are subject to change at any time, including, but not limited to, statements about Elite's expectations regarding forward operating results. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations. Actual results may differ materially.
Elite disclaims any obligation to update or revise its forward-looking statements, except as required by law. More complete information regarding forward-looking statements, risks and uncertainties can be found on reports Elite files with the SEC, which is available on the Elite's website at elitepharma.com under the Investor Relations section. Elite encourages you to review these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
